Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications
| Autor: | Inmaculada Ramírez-Macías, Esteban Orenes-Piñero, Anny Camelo-Castillo, Francisco Marín, Gregory Y.H. Lip, Vanessa Roldán, José Miguel Rivera-Caravaca |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Vitamin
microbial metabolites Microbial metabolites lcsh:Medicine Time in therapeutic range trimethylamine n-oxide Gut microbiota Review 030204 cardiovascular system & hematology Gut flora Vitamin k Bioinformatics 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Trimethylamine n-oxide Medicine In patient oral anticoagulants Oral anticoagulation 030304 developmental biology 0303 health sciences biology gut microbiota business.industry lcsh:R General Medicine biology.organism_classification Oral anticoagulants Review article vitamin k chemistry business |
| Zdroj: | Journal of Clinical Medicine Camelo-Castillo, A, Rivera-Caravaca, J M, Orenes-Piñero, E, Ramírez-Macías, I, Roldán, V, Lip, G Y H & Marín, F 2021, ' Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users : A Review of Potential Implications ', Journal of Clinical Medicine, vol. 10, no. 4, 715, pp. 1-16 . https://doi.org/10.3390/jcm10040715 Journal of Clinical Medicine, Vol 10, Iss 715, p 715 (2021) |
| ISSN: | 2077-0383 |
| DOI: | 10.3390/jcm10040715 |
| Popis: | The efficacy and safety of vitamin K antagonists (VKAs) as oral anticoagulants (OACs) depend on the quality of anticoagulation control, as reflected by the mean time in therapeutic range (TTR). Several factors may be involved in poor TTR such as comorbidities, high inter-individual variability, interacting drugs, and non-adherence. Recent studies suggest that gut microbiota (GM) plays an important role in the pathogenesis of cardiovascular diseases, but the effect of the GM on anticoagulation control with VKAs is unknown. In the present review article, we propose different mechanisms by which the GM could have an impact on the quality of anticoagulation control in patients taking VKA therapy. We suggest that the potential effects of GM may be mediated first, by an indirect effect of metabolites produced by GM in the availability of VKAs drugs; second, by an effect of vitamin K-producing bacteria; and finally, by the structural modification of the molecules of VKAs. Future research will help confirm these hypotheses and may suggest profiles of bacterial signatures or microbial metabolites, to be used as biomarkers to predict the quality of anticoagulation. This could lead to the design of intervention strategies modulating gut microbiota, for example, by using probiotics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |